enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

3. Chronic obstructive pulmonary disease - Wikipedia

   en.wikipedia.org/wiki/Chronic_obstructive...

   Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by chronic respiratory symptoms and airflow limitation. [8] GOLD 2024 defined COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea or shortness of breath, cough, sputum production or exacerbations) due to abnormalities of the airways (bronchitis ...

4. Acute exacerbation of chronic obstructive pulmonary disease

   en.wikipedia.org/wiki/Acute_exacerbation_of...

   According to a 2018 systematic review, a shorter, five-day course of systemic corticosteroids is likely comparable to longer (10–14 day) therapy for treatment of COPD exacerbation (Odds ratio (OR) 0.72, 95% confidence interval (CI) 0.36 to 1.46). [19] Theophylline is generally not recommended.

5. FDA approves new COPD drug developed by firm in Raleigh ... - AOL

   www.aol.com/news/fda-approves-copd-drug...

   A new drug developed by a company with US headquarters in Raleigh, Ohtuvayre, was approved by the FDA Wednesday to help COPD patients manage symptoms.

6. Global Initiative for Chronic Obstructive Lung Disease

   en.wikipedia.org/wiki/Global_Initiative_for...

   [1] [2] They have organized the annual awareness day, World COPD Day, every November since 2002. [3] This organization issues recommendations for the treatment of chronic obstructive pulmonary disease and related medical conditions. GOLD issued its first formal recommendations in 2001. [2]

7. US FDA approves Verona Pharma's inhaled COPD therapy - AOL

   www.aol.com/news/us-fda-approves-verona-pharmas...

   The U.S. FDA's assent for the therapy, to be sold under the brand Ohtuvayre, is the company's first and provides a new inhaled non-steroidal treatment for chronic obstructive pulmonary disease.